Two lessons I learned this week.
By Dr. Matthew Watson
I learned two valuable things this week I thought I'd pass on in a Friday afternoon post. Actually strictly speaking these are likely things I've learned before but needed to re-learn or to be 'reminded' of their importance.
Please pardon a little stroll away from the typically strict focus on cell therapy -- but in a way that's the theme of today's post.
1. Take time each week to read something from outside your specific profession or job focus.
I'm not talking here about the importance of escaping in the evening with a fiction novel (also very important) but rather reading something professional but from well outside your area of focus. Here are my examples.
I always read WIRED magazine. Aside from GEN it's the only magazine I read. Just reading something outside of cell therapy or biotech often infuses me with an idea that otherwise would have never occurred to me like the need for a cell therapy X Prize or cellular aggregates as microcarriers or tissue-engineered memory and processing devices or even just the conviction to better represent cell therapy to the broader world out there of scientists, engineers, journalists, policy-makers, or perhaps people with too much money looking to be inspired and wanting to make a difference.
Similarly, on a flight this week I reached into the seat pocket in front of me and discovered a recent copy of the Journal of the American Medical Association. I read a fascinating article that has me excited about an idea for how we as a cell therapy industry might lead the way in addressing clinical trial and data transparency that would put our sector in a leadership position, lend the industry a much-needed spotlight, and has the potential to facilitate the kind of meta-analysis and data-mining that could only be done through data aggregation. I believe the concept has the potential to be disproportionately significant for a sector defined by so many small, under-powered trials.
The idea may never see the light of day but the point is the source of the inspiration. In order to 'think' outside the box one typically has to 'be' outside the box. Lesson? Spend some time outside your box.
2. It often takes something very small to make a disproportionately significant impact on someone.
I was reminded recently through an exchange of simple kindnesses just how little it sometimes takes to make a big difference in someone's life. For you what might be so easy to give might be of unparalleled value to someone for whom that is so unattainable.
Lesson? When the opportunity knocks for you to give something small or simple, take it. This kind of charity almost always has the potential to be mre impactful than you might ever imagine.
Source:
http://feeds.feedburner.com/CellTherapyBlog
- 001 Stem cells for a Webby! [Last Updated On: April 28th, 2010] [Originally Added On: April 28th, 2010]
- 002 Latest Cell Therapy Approval by FDA. Dendreon's Provenge. [Last Updated On: April 30th, 2010] [Originally Added On: April 30th, 2010]
- 003 Google to Invest in Regenerative Medicine [Last Updated On: May 5th, 2010] [Originally Added On: May 5th, 2010]
- 004 Biotech tax credit appears perfectly designed for cell therapy companies to recoup research dollars spent in 2009-10 [Last Updated On: May 22nd, 2010] [Originally Added On: May 22nd, 2010]
- 005 The changing face of PR and why it matters to regenmed [Last Updated On: June 12th, 2010] [Originally Added On: June 12th, 2010]
- 006 FDA files injunction again Regenerative Sciences citing Regenexx violates regulations [Last Updated On: August 12th, 2010] [Originally Added On: August 12th, 2010]
- 007 Careers in cell therapy & regenerative medicine [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 008 The LinkedIn Cell Therapy Industry Group - 1,000 members strong [Last Updated On: January 15th, 2011] [Originally Added On: January 15th, 2011]
- 009 Cell Therapies: Commercializing a New Class of Biopharmaceuticals [Last Updated On: February 12th, 2011] [Originally Added On: February 12th, 2011]
- 010 In vivo cell trafficking just took a leap forward [Last Updated On: July 3rd, 2011] [Originally Added On: July 3rd, 2011]
- 011 Cell Therapy's Got Talent Technology Showcase - A Call for Cell Therapy Manufacturing Technology Presentations [Last Updated On: July 10th, 2011] [Originally Added On: July 10th, 2011]
- 012 Clinical trial costs [Last Updated On: July 31st, 2011] [Originally Added On: July 31st, 2011]
- 013 Good Data? $100. Good Product Development? $100. Good Commercialization Strategy? Priceless. [Last Updated On: August 14th, 2011] [Originally Added On: August 14th, 2011]
- 014 Potential far-reaching implications of the ongoing fight over point-of-care autologous cell therapy [Last Updated On: September 18th, 2011] [Originally Added On: September 18th, 2011]
- 015 Commercial-stage Cell Therapy Companies and Products [Last Updated On: September 18th, 2011] [Originally Added On: September 18th, 2011]
- 016 Cell Therapy & Regenerative Medicine Domains Available [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- 017 Commercializing Cell-based Regenerative Medicines [Last Updated On: November 13th, 2011] [Originally Added On: November 13th, 2011]
- 018 Sabrina Cohen Foundation Thanks Stem Cell Researchers [Last Updated On: November 27th, 2011] [Originally Added On: November 27th, 2011]
- 019 Active phase III or II/III cell therapy trials [Last Updated On: December 11th, 2011] [Originally Added On: December 11th, 2011]
- 020 Recently approved cell therapy products [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- 021 Inactive and recently failed or terminated phase III or II/III cell therapy trials [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- 022 2011 EMA Committee for Advanced Therapies (CAT) classification record. What can be learned? [Last Updated On: January 1st, 2012] [Originally Added On: January 1st, 2012]
- 023 Predicting the Success of the Late-Stage Cell-Based Cancer Immunotherapy Pipeline? [Last Updated On: March 11th, 2012] [Originally Added On: March 11th, 2012]
- 024 Another > $100M month for companies in the cell therapy space [Last Updated On: May 6th, 2012] [Originally Added On: May 6th, 2012]
- 025 Cell-based Cancer Immunotherapies. Some metrics.. [Last Updated On: May 20th, 2012] [Originally Added On: May 20th, 2012]
- 026 Industry-sponsored cardiovascular cell therapies. Some metrics. [Last Updated On: May 27th, 2012] [Originally Added On: May 27th, 2012]
- 027 Bioreactor Design and Bioprocess Controls for Industrialized Cell Processing [Last Updated On: June 17th, 2012] [Originally Added On: June 17th, 2012]
- 028 FDA 1. RSI 0. Regenerative Sciences (Regenexx) vs FDA (2012) [Last Updated On: July 29th, 2012] [Originally Added On: July 29th, 2012]
- 029 Is the cell therapy sector outperforming the major indices? [Last Updated On: August 12th, 2012] [Originally Added On: August 12th, 2012]
- 030 Are some cell counts too good to be true? Why some companies' product data may mislead. [Last Updated On: September 2nd, 2012] [Originally Added On: September 2nd, 2012]
- 031 The cost of clinical trial data bias/loss, FDA's new job and the need for bold leadership. [Last Updated On: September 30th, 2012] [Originally Added On: September 30th, 2012]
- 032 Anticipated short-term cell therapy industry clinical milestones [Last Updated On: September 30th, 2012] [Originally Added On: September 30th, 2012]
- 033 Cell therapy portfolio outperforms major indices year-to-date [Last Updated On: October 14th, 2012] [Originally Added On: October 14th, 2012]
- 034 CIRM addresses some tough questions. Is it all just glass towers and basic research? [Last Updated On: October 21st, 2012] [Originally Added On: October 21st, 2012]
- 035 GEN's "Cellular Therapy Wave Finally Cresting". An overview and data set. [Last Updated On: November 4th, 2012] [Originally Added On: November 4th, 2012]
- 036 Cell Therapy Industry Group Welcomes its 4,000th member [Last Updated On: November 11th, 2012] [Originally Added On: November 11th, 2012]
- 037 Six steps to fighting non-compliant cell therapy treatments. --- The stuff of grey shades, spades, ivory towers and (ahem) balls. [Last Updated On: December 2nd, 2012] [Originally Added On: December 2nd, 2012]
- 038 A proposed 6-step platform for the cell therapy industry to consider in combating non-compliant cell therapy treatments [Last Updated On: December 16th, 2012] [Originally Added On: December 16th, 2012]
- 039 The ROI on pant-wearing and other social media tips [Last Updated On: December 16th, 2012] [Originally Added On: December 16th, 2012]
- 040 The Accuracy of Adipose Stem Cell Doses [Last Updated On: December 23rd, 2012] [Originally Added On: December 23rd, 2012]
- 041 Cell Therapy Blog welcomes 2013 [Last Updated On: January 6th, 2013] [Originally Added On: January 6th, 2013]
- 042 2013 Annual Regenerative Medicine Industry Report [Last Updated On: April 21st, 2013] [Originally Added On: April 21st, 2013]
- 043 Commercialization of Regenerative Medicine: Learning from Spin-Outs [Last Updated On: April 28th, 2013] [Originally Added On: April 28th, 2013]

Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research